Treatment of RA patients with a chimeric monoclonal antibody against tumor necrosis factor α (TNFα; cA2) results in clinical improvement in the majority of patients. The present study was designed to determine if cA2 therapy decreases PBMC NOS2 protein expression and NOS enzyme activity in RA ...
Treatment of RA patients with a chimeric monoclonal antibody against tumor necrosis factor (TNF; cA2) results in clinical improvement in the majority of patients. The present study was designed to determine if cA2 therapy decreases PBMC NOS2 protein expression and NOS enzyme activity in RA patients...